Skip to main content

Fortrus Ltd forms strategic partnership with Bloodwise

News   •   Feb 11, 2016 08:45 GMT

Fortrus Ltd will be working in partnership with Bloodwise to help raise money in the fight against blood cancer.

With the expertise that both Fortrus and Bloodwise have within the Healthcare industry and the desire to constantly improve, we felt that together we could achieve more in the fight against blood cancers than we could alone.


'Team Fortrus' have already signed up for the Bloodwise London to Paris ride in September, I will also be doing the Bloodwise Blenheim Triathlon in June. We see this is a fantastic opportunity to get Customers and Partners involved in our fundraising activities over the coming year.

Pro Bono Support

Bloodwise work with data in many ways throughout their organisation. We plan to work together to explore and understand the best ways in which Fortrus may be able to help improve and manage the data they collect, whether that be through their supporters, clinical trials or Haematological Malignancy Research Network (HMRN). 

Working with people: Fortrus puts the user at the forefront of the systems it builds, and Bloodwise put blood cancer patients at the forefront of their research and support services. In 2013, they started what has become the most comprehensive piece of research into the needs of blood cancer patients. They identified 24 key needs, which they have already started to address. 2015 has seen the name change from Leukaemia & Lymphoma Research to Bloodwise to embrace patients suffering from all the 137 different types of blood cancer. They launched their first ever blood cancer awareness campaign to reverse the lack of awareness of blood cancer and organisations which are here to help. Over 2016 and beyond Bloodwise will be working hard to address all the unmet needs, and continue their research as these evolve.

Never stop innovating: In the same way that Fortrus is developing technologies which were thought impossible, blood cancer scientists were the first to treat patients with chemicals, via chemotherapy, which at the time was deemed “incompatible with sanity”. Their Trials Acceleration Program (TAP) has changed the game for cancer research; described as “bang on” by National Cancer Director Sean Duffy. It’s a model that’ll work for all diseases, not just blood cancers: so it could truly revolutionise clinical trials in the UK. Using a hub-and-spoke model, the University of Birmingham coordinates clinical trials in 13 centres, creating a catchment area of up to 22 million people. Acceleration of access to life-saving medicines is now part of the UK government’s Life Sciences’ agenda and the government have highlighted TAP as an example of innovation and best practice in this area.

In the next few months, the new TAP website will be launched. It will support the development of blood cancer research by providing a set of digital tools for the TAP community, which includes Bloodwise partners (researchers and hospitals), bodies such as Department of Health, National Institute for Health Research (NIHR) and the Association of Medical Research Charities (AMRC), members of the public, pharmaceutical companies and other researchers.

The website will monitor real time trial patient recruitment data; allow key documents to be shared within the TAP network; showcase the TAP approach and its benefits to the public; allow TAP researchers to share best practice; and showcase the various centres around the UK and their involvement to the public. 

Data is powerful: 20 years ago, Bloodwise invested in what is now the Haematological Malignancy Research Network (HMRN), which houses data from 20,000 blood cancer patients detailing every clinical aspect imaginable, including their symptoms, treatment, response, height, weight and lifestyle. When they first invested, they didn’t know exactly how they would use the data, but knew they’d reap the rewards in the future. So far, its enabled them to identify the biggest blood cancer killers, find out whether one type of person is more likely to get blood cancer than others and recognise links between socio-economic background and survival rates, which could be associated with some groups of people adhering to their treatment regimen better than others. They know this is the tip of the iceberg for the depth of knowledge that can be gained from this data.

Over the coming months we will be sharing news regarding the partnership, the research and the Fortrus Fundraising and Training progress.

For further information please contact:

Leigh Baillie

Chief Marketing Officer

Fotrus Ltd

+44 7894 517828

Comments (0)

Add comment


By submitting the comment you agree that your personal data will be processed according to Mynewsdesk's <a href="">Privacy Policy</a>.